Home Tags PBD

Tag: PBD

Collaboration to Explore the Safety and Efficacy of Combining Rova-T +...

A new Phase I/II clinical program in which Bristol-Myers Squibb collaborates with AbbVie will evaluate the safety, tolerability and efficacy of the investigational biomarker-specific...

ASCO 2016 Emphasizes Collective Wisdom: The Future of Patient-Centered Care and...

Only a few weeks until the start of the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). This year’s ASCO, taking...

First Patient Dosed in Phase I Trial of ADCT-402 in CD-19...

Late last week, Swiss based ADC Therapeutics, an oncology drug development company that specializes in the development of proprietary antibody-drug conjugates (ADCs) targeting major...

Improving the Potency and Toxicity Profile of Antibody-drug Conjugates

Currently, there are more than 30 antibody drug conjugates or ADCs in clinical trials, with many more expected in the near future. ADCs are...

ADC Therapeutics Raises US$ 80 million to Advance ADC Pipeline

ADC Therapeutics, an oncology drug discovery and development company headquartered in Lausanne, Switzerland and London, UK, that specializes in the development of proprietary Antibody...

A Chemistry Driven Approach to Uniform Antibody-drug Conjugates: New Data on...

Earlier today, during a plenary session of the 2015 World ADC Summit, being held October 26-29, 2014 in San Diego, California, Randall Halcomb, PhD, Vice President Chemistry at Igenica Biotherapeutics, presented new data utilizing the company's SNAP site-specific ADC linker technology.

ADC Therapeutics and Genmab Agree to Develop Antibody-drug Conjugate

Earlier this week Swiss-based oncology drug development company ADC Therapeutics Sarl and Danish Genmab A/S agreed to develop a new antibody-drug conjugate (ADC) combining HuMax®-TAC antibody...

New CD33-Directed Antibody-Drug Conjugate, Utilizing Pyrrolobenzodiazepine Dimers, Demonstrates Anti-tumor Activity in...

Preclinical data from SGN-CD33A (Seattle Genetics, Inc), a novel CD33-directed antibody-drug conjugate (ADC) in development for the treatment of acute myeloid leukemia (AML) presented at...

X